These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 30849994)

  • 21. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay.
    Argani P; Lal P; Hutchinson B; Lui MY; Reuter VE; Ladanyi M
    Am J Surg Pathol; 2003 Jun; 27(6):750-61. PubMed ID: 12766578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.
    Pflueger D; Sboner A; Storz M; Roth J; Compérat E; Bruder E; Rubin MA; Schraml P; Moch H
    Neoplasia; 2013 Nov; 15(11):1231-40. PubMed ID: 24339735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification by FFPE RNA-Seq of a new recurrent inversion leading to RBM10-TFE3 fusion in renal cell carcinoma with subtle TFE3 break-apart FISH pattern.
    Just PA; Letourneur F; Pouliquen C; Dome F; Audebourg A; Biquet P; Vidaud M; Terris B; Sibony M; Pasmant E
    Genes Chromosomes Cancer; 2016 Jun; 55(6):541-8. PubMed ID: 26998913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adult-onset renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusion with smooth muscle stroma and abnormal vessels.
    Kuroda N; Tamura M; Tanaka Y; Hes O; Michal M; Inoue K; Ohara M; Mizuno K; Lee GH
    Pathol Int; 2009 Jul; 59(7):486-91. PubMed ID: 19563413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
    Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
    Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PRCC-TFE3 regulates migration and invasion of translocation renal cell carcinomas via activation of Drp1-dependent mitochondrial fission.
    Wang B; Gan W; Han X; Li D
    Cell Biol Int; 2020 Aug; 44(8):1727-1733. PubMed ID: 32339358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
    Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
    Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
    Argani P; Hicks J; De Marzo AM; Albadine R; Illei PB; Ladanyi M; Reuter VE; Netto GJ
    Am J Surg Pathol; 2010 Sep; 34(9):1295-303. PubMed ID: 20679884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The incidence of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in Saudi adult patients with renal cancer: a retrospective tissue microarray analysis.
    Al-Maghrabi J; Mufti S; Gomaa W
    Pol J Pathol; 2018; 69(4):376-383. PubMed ID: 30786687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma.
    Damayanti NP; Cordova RA; Rupert C; Delle Fontane I; Shen L; Orsi S; Klunk AJ; Linehan WM; Staschke KA; Hollenhorst PC; Heppner DE; Pili R
    Cancer Res; 2024 Apr; 84(8):1286-1302. PubMed ID: 38266162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual role of G-quadruplex in translocation renal cell carcinoma: Exploring plausible Cancer therapeutic innovation.
    Neha ; Das P; Verma SP
    Biochim Biophys Acta Gen Subj; 2020 Dec; 1864(12):129719. PubMed ID: 32882363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.
    Wang XT; Xia QY; Ye SB; Wang X; Li R; Fang R; Shi SS; Zhang RS; Tan X; Chen JY; Sun K; Teng XD; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Mod Pathol; 2018 Sep; 31(9):1346-1360. PubMed ID: 29713041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
    Martignoni G; Pea M; Gobbo S; Brunelli M; Bonetti F; Segala D; Pan CC; Netto G; Doglioni C; Hes O; Argani P; Chilosi M
    Mod Pathol; 2009 Aug; 22(8):1016-22. PubMed ID: 19396149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3.
    Xia QY; Wang XT; Zhan XM; Tan X; Chen H; Liu Y; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Am J Surg Pathol; 2017 May; 41(5):663-676. PubMed ID: 28288037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
    Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
    Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
    Ye H; Qin S; Li N; Lin M; Xu Y; Li X
    Biomed Res Int; 2019; 2019():5974089. PubMed ID: 31828108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring G-quadruplex structure in PRCC-TFE3 fusion oncogene: Plausible use as anti cancer therapy for translocation Renal cell carcinoma (tRCC).
    Neha N; Das P
    J Biotechnol; 2024 Jul; 390():39-49. PubMed ID: 38740306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma.
    Kim SH; Choi Y; Jeong HY; Lee K; Chae JY; Moon KC
    Virchows Arch; 2011 Sep; 459(3):299-306. PubMed ID: 21773754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical features of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions-single-center study].
    Ma WL; Liu N; Zhuang WY; Li XG; Zhang GT; Gan WD; Guo HQ
    Zhonghua Yi Xue Za Zhi; 2018 Oct; 98(38):3068-3073. PubMed ID: 30392265
    [No Abstract]   [Full Text] [Related]  

  • 40. Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis.
    Liu N; Wang Z; Gan W; Xiong L; Miao B; Chen X; Guo H; Li D
    PLoS One; 2016; 11(11):e0166897. PubMed ID: 27893792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.